Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting

Matter-Walstra, K; Schwenkglenks, Matthias; Dedes, K J

doi:10.1007/s10549-017-4209-5

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting

Matter-Walstra, K; Schwenkglenks, Matthias; Dedes, K J (2017). Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast Cancer Research and Treatment, 163(3):635.

Find similar titles

Additional indexing

Item Type:	Journal Article, refereed, original work
Communities & Collections:	04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI) 04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
Dewey Decimal Classification:	610 Medicine & health
Scopus Subject Areas:	Health Sciences > Oncology Life Sciences > Cancer Research
Language:	English
Date:	June 2017
Deposited On:	04 Jan 2018 08:34
Last Modified:	21 Aug 2024 03:33
Publisher:	Springer
ISSN:	0167-6806
OA Status:	Closed
Publisher DOI:	https://doi.org/10.1007/s10549-017-4209-5
PubMed ID:	28321586